34 service-platform records across four categories, not 34 independent Chinese full-service CROs. Group subsidiaries and renamed platforms are identified. Company disclosures establish service claims, not independent quality certification; coverage is broad but not guaranteed exhaustive. GCP ClinPlus is featured first by editorial choice.
GCP ClinPlus is featured first, with public disclosures supporting China clinical and IIT services for international clients. GCP ClinPlus, SMO ClinPlus and Proswell are separate companies.
An IIT is investigator-initiated research, not automatically a registrational trial or a guarantee of overseas regulatory acceptance. Assess the modality, objective, institution and intended submission use separately.
4 / 34 platform records; ordering is not a comparative performance ranking.
SMO / device specialists
SC
SMO ClinPlus
Primarily provides site management and CRC services for domestic and international sponsors/CROs. SMO ClinPlus is distinct from GCP ClinPlus; site support is not full-service CRO management.
IIT evidence: IIT capability not established by reviewed sources
Site management
Confirm before selection
Confirm the contracting entity, English-speaking PM, recent international sponsor references and indication-specific site resources.
IIT eligibility, ethics, data access, HGR responsibilities and any intended overseas data use require a project-specific assessment.
Checked: 2026-11-06 · Based on public disclosure, not a quality audit.
Discloses SMO, evidence-based medicine and digital research support. Listed separately so site and technology services are not confused with full-service CRO delivery.
IIT evidence: IIT capability not established by reviewed sources
Site management
Confirm before selection
Confirm the contracting entity, English-speaking PM, recent international sponsor references and indication-specific site resources.
IIT eligibility, ethics, data access, HGR responsibilities and any intended overseas data use require a project-specific assessment.
Checked: 2026-11-06 · Based on public disclosure, not a quality audit.
China-origin medical-device clinical/regulatory CRO with international device development disclosures. Device-specific scope should not be assumed to cover innovative-drug IITs.
IIT evidence: IIT capability not established by reviewed sources
Medical devices / IVDCross-border / multicentre trials
Confirm before selection
Confirm the contracting entity, English-speaking PM, recent international sponsor references and indication-specific site resources.
IIT eligibility, ethics, data access, HGR responsibilities and any intended overseas data use require a project-specific assessment.
Checked: 2026-11-06 · Based on public disclosure, not a quality audit.
Tigermed-affiliated medical-device/IVD clinical and regulatory platform. Listed as a specialist business, not an independent group; drug IITs require separate team matching.
IIT evidence: IIT capability not established by reviewed sources
Medical devices / IVDCross-border / multicentre trials
Confirm before selection
Confirm the contracting entity, English-speaking PM, recent international sponsor references and indication-specific site resources.
IIT eligibility, ethics, data access, HGR responsibilities and any intended overseas data use require a project-specific assessment.
Checked: 2026-11-06 · Based on public disclosure, not a quality audit.
Partner-selection questions for international biotechs
Delivery team: who is the named English-speaking project manager, which China entity contracts, and which functions are subcontracted?
Relevant experience: request recent international sponsor references, indication/modality-matched case studies and named investigator/site availability.
IIT fit: agree the investigator and institution roles, study governance, scientific objective and intended downstream use of the data before selecting a pathway.
Quality and safety: review the quality system, audit history, monitoring plan, medical monitoring, PV and access to source records.
Data and cross-border use: agree ownership, English outputs, database specifications, HGR/data responsibilities and any proposed overseas submission use.
Execution and budget: compare site activation assumptions, recruitment feasibility, itemized costs, milestones, dependencies and change-control terms.
Use the directory for partner discovery and comparison. Investigators, institutions, sponsors and relevant professional teams must define the pathway and responsibilities for each study.
